Improved human T-cell responses against synthetic HLA-0201 analog peptides derived from the WT1 oncoprotein.
about
Non-natural and photo-reactive amino acids as biochemical probes of immune functionT cell receptor mimic antibodies for cancer therapyStructures of native and affinity-enhanced WT1 epitopes bound to HLA-A0201: Implications for WT1-based cancer therapeuticsAdoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation.A novel minigene scaffold for therapeutic cancer vaccinesUncarinic Acid C Isolated from Uncaria rhynchophylla Induces Differentiation of Th1-Promoting Dendritic Cells Through TLR4 Signaling.An analogue peptide from the Cancer/Testis antigen PASD1 induces CD8+ T cell responses against naturally processed peptide.Induction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC.Novel therapies in phase II and III trials for malignant pleural mesothelioma.Human Langerhans cells use an IL-15R-α/IL-15/pSTAT5-dependent mechanism to break T-cell tolerance against the self-differentiation tumor antigen WT1.Mapping of novel peptides of WT-1 and presenting HLA alleles that induce epitope-specific HLA-restricted T cells with cytotoxic activity against WT-1(+) leukemias.WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptidesTranslational mini-review series on vaccines: Peptide vaccines for myeloid leukaemias.Role of T cell receptor affinity in the efficacy and specificity of adoptive T cell therapies.The biological basis for immunotherapy in patients with chronic myelogenous leukemia.Improving T cell responses to modified peptides in tumor vaccinesTargeting the intracellular WT1 oncogene product with a therapeutic human antibody.Adenovirus vaccine immunotherapy targeting WT1-expressing tumors.WT1 (Wilms' tumor gene 1): biology and cancer immunotherapy.WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer.Understanding CD8+ T-cell responses toward the native and alternate HLA-A*02:01-restricted WT1 epitope.Immunotherapy in acute myeloid leukemia.Xenogene vaccination in the therapy of cancer.Analogue peptides for the immunotherapy of human acute myeloid leukemia.An immunogenic WT1-derived peptide that induces T cell response in the context of HLA-A*02:01 and HLA-A*24:02 molecules.Generation of cytotoxic T lymphocytes specific for native or modified peptides derived from the epidermal growth factor receptor pathway substrate 8 antigen.Enhancement of lytic activity of leukemic cells by CD8+ cytotoxic T lymphocytes generated against a WT1 peptide analogue.Targeting cryptic epitope with modified antigen coupled to the surface of liposomes induces strong antitumor CD8 T-cell immune responses in vivo.Unexpected T-cell recognition of an altered peptide ligand is driven by reversed thermodynamics.Advances in systemic therapy for malignant mesothelioma: future perspectives.A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma.
P2860
Q21144124-1B03FF09-8C37-477D-9838-8255EE7872D6Q26768271-EBFB42A6-9C15-4400-B6C8-7B5752F2F2F7Q27663300-86768873-3311-4D54-8181-B7747FF23C64Q34279672-16F25758-227C-4441-942B-9AE6213A20D0Q34418540-03A0D5FD-3E97-49A0-845B-EA8B6576B746Q34788912-5B78FEEA-2706-404F-96D5-BCE8D246297AQ34862104-DE28A125-103D-4561-9EE3-24148365C8B8Q34979511-589260E8-FB49-470F-B74B-CAFD89B75466Q35129535-F645A810-CB1C-4881-B3DB-CD9EF729A4C0Q36014997-140CA9C8-41A9-4811-8009-9DC95FC46BDCQ36194241-5B98B0A3-D9D6-4D3C-8853-9700C90E8DC6Q36198150-7A283362-855A-4CE4-93CE-03DB155AA69FQ36793112-5FB735C6-5277-4822-88CB-595F3CA5D624Q37107843-6A5FAB37-5954-432A-A843-07971E837BF4Q37428671-4FC97037-BC10-4D41-8314-D109D1E23C06Q37634253-9D0314A0-7240-4A36-8ED4-26C9702181DEQ37659113-5AFA9CC2-7313-48D4-BBE9-1E8E76346D7BQ37727967-D1DEF499-48CB-4774-84F8-BC93184476F2Q37731720-362D2B75-B79C-450E-B17A-91DB57E019BFQ37731754-07315567-DD67-4790-9CB5-DD3741F594F2Q37739362-08EE8327-9B2B-489E-BBE0-337AF65E1998Q38171574-1D562729-93DC-42C5-AA99-5B69BD010354Q38229368-9FEC72C3-F294-4766-8035-7A2CBBD79ADCQ38599586-8EB4D8BE-4B02-494E-9515-78720824BC80Q38739446-39E387A7-BAB7-4BAE-8A3B-78ADAEBEABE7Q38942201-5F6D40EB-9FFF-4B2B-96C7-80C65037CE44Q39886839-08EE5D8F-E277-4A6F-9F77-B7C96A49DC34Q40510640-C2F410F3-A32A-4ECC-B51A-AB524CF59888Q44447688-F02AB147-B725-4417-B09F-8AA963C8F9EAQ47912434-784C33EB-6872-4099-92CE-024F2CE89B40Q54046740-B8FF0271-D5D9-44DB-A1D9-D0B83C66F3F4
P2860
Improved human T-cell responses against synthetic HLA-0201 analog peptides derived from the WT1 oncoprotein.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Improved human T-cell response ...... ived from the WT1 oncoprotein.
@en
type
label
Improved human T-cell response ...... ived from the WT1 oncoprotein.
@en
prefLabel
Improved human T-cell response ...... ived from the WT1 oncoprotein.
@en
P2093
P2860
P356
P1433
P1476
Improved human T-cell response ...... ived from the WT1 oncoprotein.
@en
P2093
Korontsvit T
Pinilla-Ibarz J
Scheinberg DA
Zakhaleva V
P2860
P2888
P304
P356
10.1038/SJ.LEU.2404380
P577
2006-08-31T00:00:00Z
P5875
P6179
1007730618